Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  Breaking News: FDA Approves Triumeq, New Once-Daily Combination Pill
IAS 2007: Sydney, Australia; July 22-25

Key Links:

By Topic:

Search:

The 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention
SYDNEY, AUSTRALIA
JULY 22-25, 2007


Conference Research Highlights

More of the latest coverage >>

Featuring in-depth analysis from our team of expert faculty:

Daniel Berger, M.D. Edwin DeJesus, M.D. Joel Gallant, M.D.
Margaret Hoffman-Terry, M.D. Mark Holodniy, M.D., F.A.C.P., C.I.C. Graeme Moyle, M.D., M.B., B.S., Dip. G.U.M.

About This Conference

The Body's coverage of the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2007) includes a wide array of individual presentations and symposia, as well as summaries of some of the hottest topics in HIV research.

For more information on IAS 2007, please visit the conference's Web site.

Funding for coverage of this conference is provided, in part, by Abbott Laboratories, Boehringer Ingelheim and Tibotec Pharmaceuticals.


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.


multimedia from ias
Podcasts & Interviews

More than 25 interviews are available for you to read or listen to. To view our entire collection, click here.

Joel Gallant, M.D., M.P.H. Day Three & Conference Roundup: July 25, 2007
Joel Gallant, M.D., M.P.H., wraps up our CME/CE-accredited series of daily IAS 2007 recaps with a wide-ranging discussion of important studies on first-line therapy, therapy options for treatment-experienced patients, antiretrovirals in development, abacavir hypersensitivity testing and the metabolic impact of antiretroviral switching. (CME/CE credit is available for this podcast!)

Daniel Berger, M.D. Day Two: July 24, 2007
Daniel Berger, M.D., discusses thought-provoking research on recently approved antiretrovirals and drugs in development, including darunavir, MK-0518 (raltegravir), TMC278 (rilpivirine) and CCR5 inhibitors. (CME/CE credit is available for this podcast!)

Daniel Berger, M.D. Day One: July 23, 2007
In this CME/CE-accredited interview, Daniel Berger, M.D., provides a comprehensive review of some of the most significant research discussed during the first full day of conference presentations. (CME/CE credit is available for this podcast!)